Cargando…

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Detalles Bibliográficos
Autores principales:	Widge, Alicia T., Rouphael, Nadine G., Jackson, Lisa A., Anderson, Evan J., Roberts, Paul C., Makhene, Mamodikoe, Chappell, James D., Denison, Mark R., Stevens, Laura J., Pruijssers, Andrea J., McDermott, Adrian B., Flach, Britta, Lin, Bob C., Doria-Rose, Nicole A., O’Dell, Sijy, Schmidt, Stephen D., Neuzil, Kathleen M., Bennett, Hamilton, Leav, Brett, Makowski, Mat, Albert, Jim, Cross, Kaitlyn, Edara, Venkata-Viswanadh, Floyd, Katharine, Suthar, Mehul S., Buchanan, Wendy, Luke, Catherine J., Ledgerwood, Julie E., Mascola, John R., Graham, Barney S., Beigel, John H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727324/ https://www.ncbi.nlm.nih.gov/pubmed/33270381 http://dx.doi.org/10.1056/NEJMc2032195

Ejemplares similares

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
por: Doria-Rose, Nicole, et al.
Publicado: (2021)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020)

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis
por: Anderson, Evan, et al.
Publicado: (2022)

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
por: Doria-Rose, Nicole A., et al.
Publicado: (2021)

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
por: Jackson, Lisa A., et al.
Publicado: (2020)

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant
por: Edara, Venkata-Viswanadh, et al.
Publicado: (2022)

Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection
por: Lapp, Stacey A., et al.
Publicado: (2021)

Harnessing Novel Quantitative Pharmacology Approaches to Optimize the Treatment of Children With Tuberculosis
por: Seddon, James A., et al.
Publicado: (2016)

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
por: El Sahly, Hana M., et al.
Publicado: (2021)

Viewpoint: Challenges and Opportunities in Tuberculosis Research
por: Kim, Peter S., et al.
Publicado: (2012)

Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead
por: Gumbo, Tawanda, et al.
Publicado: (2016)

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
por: Hurlburt, Nicholas K., et al.
Publicado: (2020)

Nucleoside analogues for the treatment of coronavirus infections
por: Pruijssers, Andrea J, et al.
Publicado: (2019)

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021)

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273)
por: Leav, Brett, et al.
Publicado: (2022)

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
por: Corbett, Kizzmekia S., et al.
Publicado: (2020)

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS
por: Naficy, A., et al.
Publicado: (2023)

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
por: Ali, Kashif, et al.
Publicado: (2021)

Rapid Detection and Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant in a Returning Traveler
por: Sexton, Mary Elizabeth, et al.
Publicado: (2022)

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
por: Mantus, Grace, et al.
Publicado: (2022)

Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India
por: Nayak, Kaustuv, et al.
Publicado: (2021)

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
por: Chu, Laurence, et al.
Publicado: (2021)

The coronavirus proofreading exoribonuclease mediates extensive viral recombination
por: Gribble, Jennifer, et al.
Publicado: (2021)

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
por: Gagne, Matthew, et al.
Publicado: (2022)

Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers
por: Li, Mengchun, et al.
Publicado: (2020)

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
por: Giuliano, Anna, et al.
Publicado: (2023)

β-Catenin Regulates Wound Healing and IL-6 Expression in Activated Human Astrocytes
por: Edara, Venkata Viswanadh, et al.
Publicado: (2020)

Activated human astrocyte-derived extracellular vesicles modulate neuronal uptake, differentiation and firing
por: You, Yang, et al.
Publicado: (2019)

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
por: Jennewein, Madeleine F., et al.
Publicado: (2021)

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
por: Chalkias, Spyros, et al.
Publicado: (2022)

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
por: Chu, Laurence, et al.
Publicado: (2022)

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)

Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation
por: Martinez, Paola, et al.
Publicado: (2015)

Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial
por: Gilbert, Peter B., et al.
Publicado: (2021)

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial
por: Branche, Angela R., et al.
Publicado: (2023)

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
por: Pajon, Rolando, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8hotet0g476657hvrc8ji1oopi